1.Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head.
China Journal of Orthopaedics and Traumatology 2009;22(9):697-699
OBJECTIVETo observe the diagnosis and treatment of bone marrow edema syndrome and summarize its features, mechanisms and its differences from avascular necrosis of femoral head.
METHODSFrom 2004.1, 19 patients (12 patients were males and 7 patients were females, with a mean age of (46.70 +/- 10.36) years) with bone marrow edema syndrome of hip treated with Ibandronate and physical therapy, as well as scored with Harris system before and after treatment.
RESULTSAverage score before treatment was (43.17 +/- 12.62), and (86.73 +/- 14.29) after treatment, and the difference was significant (P < 0.05).
CONCLUSIONBone marrow edema syndrome of hip is different from avascular necrosis of the hip, it is a distinct clinical entity.
Adult ; Bone Density Conservation Agents ; therapeutic use ; Bone Marrow Diseases ; diagnosis ; drug therapy ; pathology ; therapy ; Diphosphonates ; therapeutic use ; Female ; Femur Head Necrosis ; diagnosis ; pathology ; Hip Joint ; drug effects ; pathology ; Humans ; Male ; Middle Aged
2.Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures.
Jun IWAMOTO ; Yoshihiro SATO ; Mitsuyoshi UZAWA ; Tsuyoshi TAKEDA ; Hideo MATSUMOTO
Yonsei Medical Journal 2009;50(4):474-481
PURPOSE: The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures. MATERIALS AND METHODS: One hundred twelve men with osteoporosis or osteopenia with clinical risk factors for fractures (mean age: 71.4 years) were randomly divided into two groups of 56 patients each: the alendronate (5 mg daily) and alfacalcidol (1 microgram daily) groups. The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the 12-month-treatment period. RESULTS: Forty-five patients in the alendronate group and 42 patients in the alfacalcidol group completed the trial. Alendronate increased BMD (+2.3% at 12 months) following reductions in the urinary level of NTX (-46.4% at 3 months) and serum level of BSAP (-34.1% at 12 months), while alfacalcidol sustained BMD (-1.9% at 12 months) as well as the urinary level of NTX (+13.2% at 3 months) and serum level of BSAP (+1.8% at 12 months). CONCLUSION: The present study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.
Aged
;
Aged, 80 and over
;
Alendronate/pharmacology/therapeutic use
;
Asian Continental Ancestry Group
;
Bone Density/*drug effects
;
*Bone Density Conservation Agents/pharmacology/therapeutic use
;
Bone Diseases, Metabolic/*drug therapy
;
Fractures, Bone/*prevention & control
;
Hip Joint/*drug effects/pathology
;
Humans
;
*Hydroxycholecalciferols/pharmacology/therapeutic use
;
Male
;
Middle Aged
;
Osteoporosis/*drug therapy
;
Treatment Outcome
3.Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures.
Jun IWAMOTO ; Yoshihiro SATO ; Mitsuyoshi UZAWA ; Tsuyoshi TAKEDA ; Hideo MATSUMOTO
Yonsei Medical Journal 2009;50(4):474-481
PURPOSE: The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures. MATERIALS AND METHODS: One hundred twelve men with osteoporosis or osteopenia with clinical risk factors for fractures (mean age: 71.4 years) were randomly divided into two groups of 56 patients each: the alendronate (5 mg daily) and alfacalcidol (1 microgram daily) groups. The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the 12-month-treatment period. RESULTS: Forty-five patients in the alendronate group and 42 patients in the alfacalcidol group completed the trial. Alendronate increased BMD (+2.3% at 12 months) following reductions in the urinary level of NTX (-46.4% at 3 months) and serum level of BSAP (-34.1% at 12 months), while alfacalcidol sustained BMD (-1.9% at 12 months) as well as the urinary level of NTX (+13.2% at 3 months) and serum level of BSAP (+1.8% at 12 months). CONCLUSION: The present study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.
Aged
;
Aged, 80 and over
;
Alendronate/pharmacology/therapeutic use
;
Asian Continental Ancestry Group
;
Bone Density/*drug effects
;
*Bone Density Conservation Agents/pharmacology/therapeutic use
;
Bone Diseases, Metabolic/*drug therapy
;
Fractures, Bone/*prevention & control
;
Hip Joint/*drug effects/pathology
;
Humans
;
*Hydroxycholecalciferols/pharmacology/therapeutic use
;
Male
;
Middle Aged
;
Osteoporosis/*drug therapy
;
Treatment Outcome